First Patient Dosed in Ph 1/2 Trial of PFL-241/STX-241 in Locally Advanced or Metastatic NSCLC patients
“The initiation of the second clinical trial in partnership with Pierre Fabre Laboratories is an important milestone as we work together to enable the rapid, global advancement of our next-generation EGFR inhibitors for difficult-to-treat NSCLC patients,” said Mark Chao, M.D., Ph.D., Chief Medical Officer of Scorpion. “PFL-241/STX-241 is a novel, CNS-penetrant and highly potent and selective treatment option for patients who develop ‘double mutant’ disease for which there is currently no approved treatment, and it’s a pleasure to partner with Pierre Fabre Laboratories, a company who shares our commitment to bringing innovative treatments to this underserved patient population. We look forward to demonstrating how PFL-241/STX-241’s differentiated preclinical profile translates into clinical benefit for patients.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us